Of 500 GPs questioned, 40% said they would not routinely increase simvastatin doses to 80mg for patients who do not reach lipid targets on a 40mg dose. Of these, 72% cited tolerability concerns as a reason for not switching patients.
NICE guidelines on lipid modification recommend that doctors should consider switching such patients to simvastatin 80mg or a drug of similar efficacy.
Over two thirds of the GPs questioned believed that more than 10% of patients on simvastatin 80mg experienced side-effects severe enough to affect their compliance with treatment.
Last week, GP reported findings suggesting that the 80mg dose of simvastatin increased patients’ risk of myopathy.
Comment below and tell us what you think